Marico Increases Stake in Satiya Nutraceuticals to 84.09%

Marico Ltd has completed an additional acquisition of 24.09% in Satiya Nutraceuticals for Rs 1,012.03 crore.
The total consideration for Marico's now 84.09% stake in the health and wellness firm is Rs 1,392.07 crore.

Reader Takeaway: Marico scales its presence in the high-growth wellness market while maintaining a clear, phased integration timeline for PLIX.

What just happened

Marico Ltd has moved from a 60% stake to an 84.09% stake in Satiya Nutraceuticals, the entity behind the PLIX brand. The transaction, completed on October 5, 2026, involved a cash consideration of Rs 1,012.03 crore. This is part of a larger plan that includes the acquisition of the final 14.09% stake in July 2027, which carries a base consideration of up to Rs 592 crore.

Why this matters

The deal highlights Marico's aggressive push into the premium health, wellness, and personal care segments. By tightening its control over Satiya Nutraceuticals, Marico is securing a stronger foothold in the modern consumer space where PLIX has shown significant growth, with turnover rising from Rs 155.32 crore in FY24 to Rs 864.31 crore in FY26.

Governance and Related Parties

Marico has clarified that the transaction is classified as a related party deal, though it confirms the transaction was conducted at arm's length. The company also stated that its own promoters and promoter group hold no interest in Satiya Nutraceuticals, ensuring transparency in the capital allocation process.

What to track next

Investors should monitor the integration of the PLIX brand into Marico’s broader financial results. Watch for how the increased stake impacts consolidated revenue growth and margin expansion in the upcoming quarterly reports, especially as the brand scales further.